112 results about "Mycoplasmata" patented technology

The invention discloses a CRISPR / Cas12a kit and a detection method for rapid detection of nucleic acid of mycoplasma pneumoniae. The CRISPR / Cas12a kit comprises a CRISPR / Cas12a detection system, wherein the CRISPR / Cas12a detection system comprises specific crRNA aiming at mycoplasma pneumoniae, a CRISPR / Cas12a protein and a single-stranded DNA reporting system, wherein the specific crRNA is any one or more designed and synthesized according to mycoplasma pneumoniae dsDNA sites, and the single-stranded DNA reporting system comprises am ssDNA FQ reporter used for fluorescence detection of a microplate reader and / or an ssDNA DB reporter used for immunogold test strip detection. According to the invention, CRISPR / Cas12a is firstly adopted to detect the nucleic acid sequence of mycoplasma pneumoniae, and has the advantages of high sensitivity, strong specificity, short time consumption, no dependence on large-scale experimental equipment and the like.

The invention discloses a preparation technology of a mycoplasma ovipneumoniae inactivated vaccine, which is based on the improvement on the preparation technology of the mycoplasma ovipneumoniae inactivated vaccine, and provides a preparation method of the mycoplasma ovipneumoniae inactivated vaccine. Through the application of the method provided by the invention, an ideal efficient mycoplasma ovipneumoniae inactivated vaccine adjuvant is screened, the content of toxin in antigen is greatly reduced, and the vaccine safety is improved. After the vaccine is applied to sheep, the antibody is generated early, the titer is high, the duration is long, and the mycoplasma ovipneumoniae infection can be effectively prevented and controlled.

The invention belongs to the field of control of animal borne diseases, and relates to a mutant having reduced adhesive ability and with a deleted mycoplasma bovis gene. The protein gene Mbov_0503 isobtained by cloning from a mycoplasma bovis HB0801 genome. According to the partiality of escherichia coli for codons, the Mbov_0503 gene is modified, and mycoplasma bovis tryptophan codon UGA is mutated into a codon UGG for coding tryptophan in the escherichia coli to obtain a recombinant protein Mbov0503. The sequence of the protein gene which is cloned is shown as SEQID NO:13, and the sequenceof the coded protein is shown as SEQID NO:14. The mutant provided by the invention is an adhesion deficient strain screened from a mutant bank. The mutant has adhesive ability for host EBL cells, andcompared with a wild strain, for the mutant disclosed by the invention, the transmembrane transmission capacity for MDBK cells and the destructivity for tight connection between cells are notably reduced. The mutant can be applied to pathopoiesis and control of the mycoplasma bovis.

The invention relates to an external nasal cavity protective agent used for allergic rhinitis, acute rhinitis and other nasal cavity and respiratory mucosa inflammations. The using method of the protective agent comprises the step of daubing the protective agent on the front section of the nasal cavity. The nasal cavity protective agent comprises the following components in percentage by weight: 2-30 percent of eucalyptus oil, 2-30 percent of tea tree oil, 2-30 percent of peppermint oil, 2-30 percent of lavender oil, 1-2 percent of enteromorpha oil and 40-90 percent of edible plant oil. The external nasal cavity protective agent has the functions that 1, the protective agent has the antihistamine function, has high effect on allergic rhinitis, acute rhinitis and the like and is fast in effect and durable in effect; 2, the nasal cavity and respiratory mucosa can be activated, and the capacity of the respiratory mucosa for resisting microbial infection is improved; 3, the nasal cavity biological environment is improved, the other symptoms of the nasal cavity are relieved, and the mucosa wound healing is promoted; 4, the protective agent has the functions of inhibiting bacteria, moulds, mycoplasma, viruses and other microbes; 5, the protective agent has the protective functions of delaying water evaporation and isolating sensitizing and pathogenic factors on the nasal cavity mucosa; 6, the protective agent is highly safe to human mucosa tissue and has a health-care function; and 7, the protective agent is convenient to use and high in economical efficiency.